By Sabela Ojea
Shares of Ardelyx rose after the company disclosed that its chairman, David Mott, has increased its stake in the company.
The stock was up 7.1%, to $5.41, in Wednesday post-market trading. Through the close, shares have dropped 41% over the past 12 months.
Mott, who has served as the biotechnology's chairman of the board since 2009, acquired 199,000 shares in the company, according to a Securities and Exchange Commission filing.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 22, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。